Literature DB >> 23934221

Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality.

Sam Norton1, Amanda Sacker, Josh Dixey, John Done, Peter Williams, Adam Young.   

Abstract

OBJECTIVE: This study aimed to identify subgroups with distinct trajectories of functional (HAQ) progression over 10 years following diagnosis of RA and identify baseline characteristics associated with the trajectories and their prognostic value for mortality.
METHODS: Between 1986 and 1998, 1460 patients with RA symptoms <2 years and prior to disease-modifying treatment (DMARDs) were recruited to an inception cohort (Early RA Study). Standard clinical, functional and laboratory assessments were performed at presentation and annually. Deaths were tracked by the National Health Service Central Register. Growth mixture modelling was used to identify distinct trajectories of HAQ score progression and survival analysis employed to compare all-cause mortality across the trajectory classes.
RESULTS: Four HAQ score progression classes were identified: moderate increasing (46%), low stable (6%), moderate stable (28%) and high stable (20%). Only the moderate-increasing class exhibited an accelerated decline in function over normal ageing. Compared with the moderate-increasing class, individuals with high-stable HAQ scores were more likely to be female, have more severe disease and other coexistent conditions. Low-stable class patients were more likely to be male and report less pain. The high-stable class had increased risk of mortality compared with the moderate-increasing class after adjusting for potential confounding factors, whereas low-stable and moderate-stable classes were at reduced mortality risk.
CONCLUSION: The effect of RA on function is set within the first few years and is affected by comorbidity. Identifying distinct groups of patients may help to target those at greater risk of poor functional outcome and mortality.

Entities:  

Keywords:  HAQ; disability; function; growth mixture model; rheumatoid arthritis

Mesh:

Year:  2013        PMID: 23934221     DOI: 10.1093/rheumatology/ket253

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  18 in total

Review 1.  Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Iñigo Bermejo; Shijie Ren; Emma Simpson; Mark Clowes; David L Scott; Adam Young; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

2.  Replicating Health Economic Models: Firm Foundations or a House of Cards?

Authors:  Inigo Bermejo; Paul Tappenden; Ji-Hee Youn
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

3.  [How frequent are poor prognostic markers in rheumatoid arthritis? : An estimate based on three epidemiologic cohorts].

Authors:  K Albrecht; A Richter; Y Meissner; D Huscher; L Baganz; K Thiele; M Schneider; A Strangfeld; A Zink
Journal:  Z Rheumatol       Date:  2017-06       Impact factor: 1.372

4.  Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register.

Authors:  Sarah Twigg; Elizabeth M A Hensor; Paul Emery; Alan Tennant; Ann W Morgan
Journal:  J Rheumatol       Date:  2017-07-01       Impact factor: 4.666

Review 5.  Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Iñigo Bermejo; Matt Stevenson; Rachel Archer; John W Stevens; Edward Goka; Mark Clowes; David L Scott; Adam Young
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

6.  The point of no return? Functional disability transitions in patients with and without rheumatoid arthritis: A population-based cohort study.

Authors:  Elena Myasoedova; John M Davis; Vanessa L Kronzer; Rachel E Giblon; Elizabeth J Atkinson; Nathan K LeBrasseur; Cynthia S Crowson
Journal:  Semin Arthritis Rheum       Date:  2021-12-31       Impact factor: 5.431

Review 7.  Cardiac Impairment in Rheumatoid Arthritis and Influence of Anti-TNFα Treatment.

Authors:  Ivica Lazúrová; Ľubomír Tomáš
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

Review 8.  Chronic Inflammation in Rheumatoid Arthritis and Mediators of Skeletal Muscle Pathology and Physical Impairment: A Review.

Authors:  Beatriz Y Hanaoka; Matthew P Ithurburn; Cody A Rigsbee; S Louis Bridges; Douglas R Moellering; Barbara Gower; Marcas Bamman
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-01-04       Impact factor: 4.794

9.  Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response.

Authors:  Sebastien Viatte; Darren Plant; Buhm Han; Bo Fu; Annie Yarwood; Wendy Thomson; Deborah P M Symmons; Jane Worthington; Adam Young; Kimme L Hyrich; Ann W Morgan; Anthony G Wilson; John D Isaacs; Soumya Raychaudhuri; Anne Barton
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

10.  Central Aspects of Pain in Rheumatoid Arthritis (CAP-RA): protocol for a prospective observational study.

Authors:  Onosi S Ifesemen; Daniel F McWilliams; Eamonn Ferguson; Richard Wakefield; Kehinde Akin-Akinyosoye; Deborah Wilson; Dorothy Platts; Susan Ledbury; David A Walsh
Journal:  BMC Rheumatol       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.